Abstract Background Management of dyslipidemia is the primary recommend in current guidelines patients with coronary heart disease (CHD). Despite intense statins therapy, low-density lipoprotein cholesterol (LDL-C) level more than 1.8 mmol/L still have residual risk. Premature triple-vessel (PTVD) a severe CHD. Recent studies established that both risks and PTVD were associated adverse cardiova...